Scientists are investigating how non-intoxicating cannabinoids, including cannabidiol (CBD), cannabigerol (CBG) and cannabichromene (CBC), interact with the body’s endocannabinoid system, which helps regulate appetite, metabolism and immune activity. Laboratory and animal studies suggest these compounds may influence inflammation, oxidative stress and intestinal barrier function, prompting interest in conditions such as inflammatory bowel disease. However, evidence from human trials remains limited, and perceived symptom relief does not necessarily mean a disease has improved. CBD absorption can also vary considerably with food intake, while safety concerns include potential liver effects and interactions with medicines. Researchers emphasise the need for larger clinical trials to establish effectiveness, appropriate dosing and long-term safety before cannabinoid supplements can be recommended routinely.
Read more at NewsMedical